NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis $6.12 +0.19 (+3.12%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Myriad Genetics Stock (NASDAQ:MYGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Myriad Genetics alerts:Sign Up Key Stats Today's Range$5.93▼$6.1650-Day Range$3.84▼$6.3252-Week Range$3.76▼$29.30Volume460,312 shsAverage Volume1.72 million shsMarket Capitalization$568.94 millionP/E RatioN/ADividend YieldN/APrice Target$12.45Consensus RatingHold Company Overview Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah. Read More Myriad Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreMYGN MarketRank™: Myriad Genetics scored higher than 73% of companies evaluated by MarketBeat, and ranked 279th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 4 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageMyriad Genetics has received no research coverage in the past 90 days.Read more about Myriad Genetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Myriad Genetics are expected to remain at ($0.30) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Myriad Genetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.36% of the float of Myriad Genetics has been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Myriad Genetics has recently increased by 12.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.60 Percentage of Shares Shorted9.36% of the float of Myriad Genetics has been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Myriad Genetics has recently increased by 12.43%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.84 News SentimentMyriad Genetics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Myriad Genetics this week, compared to 8 articles on an average week.Search Interest7 people have searched for MYGN on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows1 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Myriad Genetics' insider trading history. Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYGN Stock News HeadlinesMyriad Genetics to Participate in Upcoming Investor Healthcare ConferencesAugust 27 at 4:05 PM | globenewswire.comANGLE plc partners with Myriad Genetics to advance cancer diagnosticsAugust 20, 2025 | msn.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 28 at 2:00 AM | Timothy Sykes (Ad)ANGLE (ANPCF) Partners with Myriad Genetics to Enhance Cancer DiagnosticsAugust 20, 2025 | gurufocus.comANGLE Announces Collaboration with Myriad Genetics | ANPCY Stock NewsAugust 20, 2025 | gurufocus.comMyriad Genetics reaffirms FY25 guidanceAugust 19, 2025 | msn.comMyriad Genetics, Inc.: Myriad Genetics Appoints Ben Wheeler Chief Financial OfficerAugust 18, 2025 | finanznachrichten.deMyriad Genetics Appoints Ben Wheeler Chief Financial Officer | MYGN Stock NewsAugust 18, 2025 | gurufocus.comSee More Headlines MYGN Stock Analysis - Frequently Asked Questions How have MYGN shares performed this year? Myriad Genetics' stock was trading at $13.71 at the beginning of the year. Since then, MYGN stock has decreased by 55.4% and is now trading at $6.1150. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.02. The firm's revenue was down 33.6% on a year-over-year basis. Read the conference call transcript. Does Myriad Genetics have any subsidiaries? Myriad Genetics subsidiaries include Counsyl, Myriad Women’s Health, Assurex Health Inc., Myriad Neuroscience, Sividon Diagnostics, Privatklinik Dr. Robert Schindlbeck, Crescendo Bioscience, and more. Who are Myriad Genetics' major shareholders? Myriad Genetics' top institutional investors include Glenview Capital Management LLC (4.93%), Geode Capital Management LLC (2.41%), Qube Research & Technologies Ltd (2.21%) and Camber Capital Management LP (2.15%). Insiders that own company stock include Paul J Diaz, Richard Bryan Riggsbee, Nicole Lambert, Heinrich Dreismann, Lee Nisley Newcomer, Colleen F Reitan and Daniel K Spiegelman. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Myriad Genetics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Netflix (NFLX). Company Calendar Last Earnings5/06/2025Today8/28/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Price Target for Myriad Genetics$12.45 High Price Target$21.00 Low Price Target$6.00 Potential Upside/Downside+110.0%Consensus RatingHold Rating Score (0-4)2.21 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.30 million Net Margins-47.45% Pretax Margin-50.47% Return on Equity-5.17% Return on Assets-3.44% Debt Debt-to-Equity RatioN/A Current Ratio1.42 Quick Ratio1.28 Sales & Book Value Annual Sales$837.60 million Price / Sales0.66 Cash Flow$1.02 per share Price / Cash Flow5.81 Book Value$4.17 per share Price / Book1.42Miscellaneous Outstanding Shares93,040,000Free Float90,812,000Market Cap$551.73 million OptionableOptionable Beta1.89 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:MYGN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.